TrialAnnals of oncology : official journal of the European Society for Medical Oncology2018

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.

D A Yardley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.